ATE295180T1 - Zubereitung zur immunisierung gegen den aids- virus - Google Patents

Zubereitung zur immunisierung gegen den aids- virus

Info

Publication number
ATE295180T1
ATE295180T1 AT01976378T AT01976378T ATE295180T1 AT E295180 T1 ATE295180 T1 AT E295180T1 AT 01976378 T AT01976378 T AT 01976378T AT 01976378 T AT01976378 T AT 01976378T AT E295180 T1 ATE295180 T1 AT E295180T1
Authority
AT
Austria
Prior art keywords
immunization against
preparation
aids virus
pharmaceutical composition
composition
Prior art date
Application number
AT01976378T
Other languages
English (en)
Inventor
Jean Haensler
Francois Dalencon
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Application granted granted Critical
Publication of ATE295180T1 publication Critical patent/ATE295180T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
AT01976378T 2000-10-06 2001-10-08 Zubereitung zur immunisierung gegen den aids- virus ATE295180T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012808A FR2814958B1 (fr) 2000-10-06 2000-10-06 Composition vaccinale
PCT/FR2001/003096 WO2002028427A2 (fr) 2000-10-06 2001-10-08 Composition pharmaceutique pour l'immunisation contre le sida

Publications (1)

Publication Number Publication Date
ATE295180T1 true ATE295180T1 (de) 2005-05-15

Family

ID=8855083

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01976378T ATE295180T1 (de) 2000-10-06 2001-10-08 Zubereitung zur immunisierung gegen den aids- virus
AT01976380T ATE350057T1 (de) 2000-10-06 2001-10-08 Impfstoffzusammesetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01976380T ATE350057T1 (de) 2000-10-06 2001-10-08 Impfstoffzusammesetzung

Country Status (12)

Country Link
US (3) US20030190326A1 (de)
EP (2) EP1326635B1 (de)
AT (2) ATE295180T1 (de)
AU (2) AU2001295673A1 (de)
CA (1) CA2424836A1 (de)
CY (1) CY1105943T1 (de)
DE (2) DE60110822T2 (de)
DK (1) DK1326636T3 (de)
ES (2) ES2240526T3 (de)
FR (1) FR2814958B1 (de)
PT (2) PT1326635E (de)
WO (2) WO2002028427A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (de) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1733735B1 (de) * 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Verfahren und Produkte zur Induktion von mukosaler Immunität
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
EP2204186B1 (de) 1999-02-17 2016-04-06 CSL Limited Immunogene Komplexe und damit zusammenhängende Verfahren
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
AU3108001A (en) * 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
WO2006033665A1 (en) * 2004-03-16 2006-03-30 Inist Inc. Tat-based vaccine compositions and methods of making and using same
WO2005090392A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based tolerogen compositions and methods of making and using same
SG177000A1 (en) * 2001-08-17 2012-01-30 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
TWI235440B (en) * 2004-03-31 2005-07-01 Advanced Semiconductor Eng Method for making leadless semiconductor package
EP2484374A1 (de) * 2004-07-18 2012-08-08 CSL Limited Immunstimulierender Komplex und Oligonucleotidformulierungen zur Induzierung verbesserter Interferon-Gamma-Antworten
US20060165717A1 (en) * 2005-01-25 2006-07-27 Sanofi Pasteur DCchol in newborns
FR2881050B1 (fr) * 2005-01-25 2007-02-23 Sanofi Pasteur Sa Dcchol chez les nouveaux-nes
US20090117132A1 (en) * 2005-07-07 2009-05-07 Pfizer, Inc. Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
DK2411043T3 (da) 2009-03-23 2013-10-21 Pin Pharma Inc Behandling af cancer med immunostimulatorisk hiv tat derivat-polypeptider
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
FR2781160B1 (fr) * 1998-07-03 2000-08-18 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
FR2783170B1 (fr) * 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
CA2363141C (en) * 1999-02-26 2010-04-06 Chiron Corporation Microemulsions with adsorbed macromolecules and microparticles
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
DE60036950T2 (de) * 1999-08-27 2008-08-07 Inex Pharmaceuticals Corp., Burnaby Zusammensetzungen zur stimulation der zytokin sekretion und zur induktion einer immunantwort
US20050249794A1 (en) * 1999-08-27 2005-11-10 Semple Sean C Compositions for stimulating cytokine secretion and inducing an immune response
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1

Also Published As

Publication number Publication date
CY1105943T1 (el) 2011-04-06
EP1326636A2 (de) 2003-07-16
ATE350057T1 (de) 2007-01-15
AU2001295671A1 (en) 2002-04-15
DK1326636T3 (da) 2007-04-30
CA2424836A1 (en) 2002-04-11
FR2814958A1 (fr) 2002-04-12
ES2275738T3 (es) 2007-06-16
US20030190326A1 (en) 2003-10-09
AU2001295673A1 (en) 2002-04-15
WO2002028427A3 (fr) 2003-03-20
WO2002028427A2 (fr) 2002-04-11
US20040038922A1 (en) 2004-02-26
ES2240526T3 (es) 2005-10-16
PT1326636E (pt) 2007-02-28
DE60125797T2 (de) 2007-12-06
DE60110822D1 (de) 2005-06-16
EP1326636B1 (de) 2007-01-03
WO2002028428A3 (fr) 2003-02-20
PT1326635E (pt) 2005-08-31
DE60125797D1 (de) 2007-02-15
FR2814958B1 (fr) 2003-03-07
EP1326635A2 (de) 2003-07-16
EP1326635B1 (de) 2005-05-11
DE60110822T2 (de) 2006-05-11
US20050118188A1 (en) 2005-06-02
WO2002028428A2 (fr) 2002-04-11

Similar Documents

Publication Publication Date Title
ATE295180T1 (de) Zubereitung zur immunisierung gegen den aids- virus
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
DK1283700T3 (da) Farmaceutiske sustained release-præparater til parenteral administration af biologisk aktive hydrofile forbindelser
BR0113822A (pt) Vacina
HUP0203056A1 (hu) Vakcinakészítmény
NO20091761L (no) Viruskapsomervaksine, fremgangsmate for fremstilling samt anvendelse derav
EP2066332A4 (de) Grippeimpfstoff-mischung aus mannan und einem grippe-antigen
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
WO1997005899A3 (en) Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
WO2006024240A3 (es) Composición vacunal contra el virus de la hepatitis c.
ATE372129T1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
WO2005097179A3 (fr) Antigene tat stabilise et ses applications pour la vaccination anti-vih.
TW200509964A (en) VP1 of foot-and-mouth disease virus
DE602004025103D1 (de) Heilkräuterzusammensetzung zur Behandlung von AIDS
ES2155510T3 (es) Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion.
WO2004031222A3 (en) Dna vaccine encoding at least two nonstructural early proteins of papillomavirus
DE60216958D1 (de) Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen
WO2002096940A3 (en) Attenuated very virulent infectious bursal disease virus
FR2818648B1 (fr) Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
AU2001270226A1 (en) Tolerance and chronic hepatitis c virus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1326635

Country of ref document: EP

REN Ceased due to non-payment of the annual fee